H1975 cells [59] exhibit epithelial morphology and harbor key mutations in the epidermal growth factor receptor (EGFR) and TP53 genes, including the EGFR exon 21 L858R mutation, which is known to confer enhanced sensitivity to EGFR inhibitors, which is a common therapeutic strategy for NSCLC. The gene discussed is TP53; the disease is non-small cell lung carcinoma.